Propanc Biopharma, a biopharmaceutical company focused on developing novel cancer treatments for patients with recurring and metastatic cancer, has announced that it is entering into a transformational stage as it prepares to file a Form 10-K annual report. The report will include recent developments and forecast for 2023/24. Propanc's lead product candidate PRP targets and eradicates cancer stem cells while leaving healthy stem cells alone. The company has raised approximately $23m through financing options that have enabled them to advance their planned R&D activities while furthering strategic collaborations to commercialize PRP.
PRP does not exhibit the same severe or even serious side effects compared to standard therapies such as chemotherapy and radiotherapy – no hair loss, no nausea, no immune suppression – which is an important consideration for patients and their loved ones. Propanc also plans to undertake joint research programs with universities in Granada and Jaén, Spain called “POP1," whose objective is to produce a fully synthetic recombinant back up clinical compound to PRP.